Development of a Gectosome Therapy for Cardiovascular Diseases

心血管疾病的基因组疗法的开发

基本信息

  • 批准号:
    10384422
  • 负责人:
  • 金额:
    $ 31.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to these existing therapies. There is no cure for hoFH, and few options are available to treat the diseases. Angiopoietin-like 3 (ANGPTL3) has emerged as a possible therapeutic target for hoFH as individuals deficient in ANGPTL3 do not develop coronary atherosclerotic plaque. The RNA targeting CRISPR enzyme LwaCas13 can turn off genes by RNA depletion analogous to RNAi but with very lower rate of off-target gene silencing. The absence of safe delivery methods currently limits the therapeutic potential of LwaCas13. The Liu laboratory at the University of Colorado-Boulder developed an innovative intracellular biologics delivery system called Gectosomes. The overall objective of this phase I STTR project is to demonstrate that silencing of ANGPTL3 by gectosome delivery of LwaCas13a/ANGPTL3 crRNA is efficacious in lowering LDL-C with acceptable safety profile in mice. The proposed strategy combines two innovative technologies for potential clinical translation. The proposed studies are feasible based on our previous success with gectosome delivery of CRISPR RNP that causes inactivation of PCSK9 in mouse liver. ANGPTL3 is primarily expressed in hepatocytes and secreted into the bloodstream. The liver is readily accessible by gectosomes. LwaCas13a-mediated RNA depletion is reversible and may have fewer safety concerns than gene editing. We will determine the efficacy and safety of ANGPTL3 suppression by LwaCas13a in mice and this work is necessary for further studies to advance a potential therapeutic solution for a rare disease.
项目摘要 Vesicle Therapeutics Inc旨在开发和商业化一种新的治疗纯合子 家族性高胆固醇血症(hoFH)。大多数hoFH是由两个等位基因的突变引起的 低密度脂蛋白受体(LDL receptor,LDLR)由于他汀类药物和PCSK 9的疗效 抗体治疗在很大程度上取决于功能性LDL受体,hoFH患者表现出有限的 对现有疗法的反应。hoFH没有治愈方法,可用的选择很少 来治疗疾病血管生成素样3(ANGPTL 3)已成为一种可能的治疗方法, hoFH靶点,因为ANGPTL 3缺陷个体不会发生冠状动脉粥样硬化 斑块靶向CRISPR酶LwaCas 13的RNA可以通过RNA耗尽关闭基因 类似于RNAi,但具有非常低的脱靶基因沉默率。安全的缺席 递送方法目前限制了LwaCas 13的治疗潜力。刘实验室在 科罗拉多大学博尔德分校开发了一种创新的细胞内生物制剂输送系统 叫做Gectosomes。第一阶段STTR项目的总体目标是证明, 通过LwaCas 13 a/ANGPTL 3 crRNA的外泌体递送来沉默ANGPTL 3有效地抑制ANGPTL 3的表达。 降低LDL-C,在小鼠中具有可接受的安全性特征。拟议战略结合了两个 创新技术,用于潜在的临床翻译。建议的研究是可行的 我们之前成功地用CRISPR RNP的外泌体递送, 小鼠肝脏中的PCSK 9。ANGPTL 3主要在肝细胞中表达,并分泌到肝细胞中。 血流肝易于被外泌体接近。LwaCas 13 a介导的RNA耗竭 是可逆的,并且可能比基因编辑具有更少的安全性问题。康贝特人将以 LwaCas 13 a在小鼠中抑制ANGPTL 3的有效性和安全性,这项工作是必要的 进一步研究,以推进一种罕见疾病的潜在治疗方案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

XUEDONG LIU其他文献

XUEDONG LIU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('XUEDONG LIU', 18)}}的其他基金

Neuron Specific mRNA Transfer With Fusogenic Microvesicles
使用融合微泡进行神经元特异性 mRNA 转移
  • 批准号:
    10578732
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Programmable Microvesicles for Intracellular Macromolecule Delivery
用于细胞内大分子递送的可编程微泡
  • 批准号:
    10350387
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Programmable Microvesicles for Intracellular Macromolecule Delivery
用于细胞内大分子递送的可编程微泡
  • 批准号:
    10544761
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Programmable Microvesicles for Intracellular Macromolecule Delivery
用于细胞内大分子递送的可编程微泡
  • 批准号:
    10798752
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Neuron Specific mRNA Transfer With Fusogenic Microvesicles
使用融合微泡进行神经元特异性 mRNA 转移
  • 批准号:
    10451377
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Programmable Microvesicles for Intracellular Macromolecule Delivery
用于细胞内大分子递送的可编程微泡
  • 批准号:
    10676021
  • 财政年份:
    2022
  • 资助金额:
    $ 31.68万
  • 项目类别:
Quantitative Analysis of Mechanochemical Signaling in Wound Response
伤口反应中机械化学信号的定量分析
  • 批准号:
    9303654
  • 财政年份:
    2016
  • 资助金额:
    $ 31.68万
  • 项目类别:
FACSAria Fusion Cell Sorter
FACSAria 融合细胞分选仪
  • 批准号:
    9075287
  • 财政年份:
    2016
  • 资助金额:
    $ 31.68万
  • 项目类别:
Quantitative Analysis of Mechanochemical Signaling in Wound Response
伤口反应中机械化学信号的定量分析
  • 批准号:
    9353292
  • 财政年份:
    2015
  • 资助金额:
    $ 31.68万
  • 项目类别:
Quantitative Analysis of Mechanochemical Signaling in Wound Response
伤口反应中机械化学信号的定量分析
  • 批准号:
    8913630
  • 财政年份:
    2015
  • 资助金额:
    $ 31.68万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了